{
    "persona": "neutral",
    "model": "llama2:70b-chat-q6_K",
    "topic": "healthcare",
    "language": "English",
    "text": "@Migraine_ResearchExciting news for migraine sufferers! ğŸ¤© New data reveals that atogepant, an oral calcitonin gene-related peptide receptor antagonist, significantly reduces monthly migraine days. 70% of patients achieved a 50% reduction in migraines with daily 60mg doses! ğŸ’ŠğŸ‘The study showed sustained efficacy over 48 weeks, with an average 8.5-day reduction in monthly migraine days. ğŸ“‰ğŸ’¯This 1-year data provides hope for patients and clinicians alike! ğŸŒŸ What are your thoughts on this breakthrough? Share your experiences or questions below! ğŸ’¬",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "5ab2482b71c59ecac92a15e26ceefea6b850d4226ecf913d"
}